1150. Resistance Analysis in the COMET-TAIL Study: Participants with Mild-to-Moderate COVID-19 Treated with Intramuscular or Intravenous Sotrovimab

BACKGROUND: Sotrovimab (VIR-7831) is an engineered human monoclonal antibody targeting a conserved region of the SARS-CoV-2 spike protein; it has been shown to have a favorable safety profile and be effective for early treatment of high-risk COVID-19 patients. The COMET-TAIL phase 3 study evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Agostini, Maria L, Schnell, Gretja, di Iulio, Julia, Kohli, Anita, Shapiro, Adrienne E, Sarkis, Elias H, Inman, Dave, Peppercorn, Amanda, Skingsley, Andrew, Gaffney, Leah A, Aldinger, Melissa, Hebner, Christy M, Cathcart, Andrea L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752326/
http://dx.doi.org/10.1093/ofid/ofac492.988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752326/
http://dx.doi.org/10.1093/ofid/ofac492.988

Ejemplares similares